Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год
Применить Всего найдено 15. Отображено 15.
28-02-2019 дата публикации

COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE"-DEPENDENT SIGNALLING

Номер: US20190062365A1
Автор: CANHAM Stephen M., Dubensky, Gauthier Kelsey, Glickman Laura Hix, JR. Thomas W., Kanne David, Katibah George Edwin, Leong Justin, McKenna Jeffrey, McWhirter Sarah M., Ndubaku Chudi Obioma, SUNG Leonard
Принадлежит:

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′- or 3′-mono-fluoro substituted, or 2′3′-di-fluoro substituted mixed linkage 2′,5′-3′,5′ CDNs. 3. The compound according to or , wherein R3 and R4 are independently —OH or —F , provided that at least one of R3 and R4 is —F.6. The compound according to or , wherein R3a and R4a are independently —OH or —F , provided that at least one of R3a and R4a is —F.10. The compound according to any one of - , wherein R3b and R4b are independently —OH or —F , provided that at least one of R3b and R4b is —F.26. A composition comprising one or more compounds according to any one of - and a pharmaceutically acceptable excipient.27. A composition according to claim 26 , wherein the composition does not include an agent that enhances cellular permeability of the one or more compounds or an agent that enhances uptake of the one or more compounds into a cell.28. A composition comprising one or more compounds according to any one of - and a delivery vehicle which enhances cellular uptake and/or stability of the compound.29. The composition according to claim 28 , wherein the delivery vehicle comprises one or more agents selected from the group consisting of lipids claim 28 , liposomes claim 28 , interbilayer crosslinked multilamellar vesicles claim 28 , biodegradable poly(D claim 28 ,L-lactic-co-glycolic acid) [PLGA]-based or poly anhydride-based nanoparticles or microparticles claim 28 , and nanoporous particle-supported lipid bilayers.30. A composition comprising one or more compounds according to any one of - and ...

Подробнее
Номер записи: 1
08-03-2018 дата публикации

COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE" - DEPENDENT SIGNALLING

Номер: US20180064745A1
Автор: Dubensky, Gauthier Kelsey, Glickman Laura Hix, JR. Thomas W., Kanne David, Katibah George Edwin, Leong Justin, McWhirter Sarah M., SUNG Leonard
Принадлежит: Aduro Biotech, Inc.

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes), In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′-fluoro substituted, bis-3′,5′CDNs, and most preferably one or more 2′,2″-diF-Rp,Rp, bis-3′,5′CDNs. 4. The compound according to claim 3 , wherein R21 and R22 are both adenine.5. The compound according to claim 3 , wherein R21 is adenine and R22 is guanine.8. The compound according to claim 1 , wherein the compound is the sodium claim 1 , potassium claim 1 , calcium claim 1 , magnesium claim 1 , zinc claim 1 , aluminum claim 1 , ammonium claim 1 , diethylamine claim 1 , olamine claim 1 , benzathine claim 1 , benethamine claim 1 , tromethamine (2-amino-2-(hydroxymethyl)propane-1 claim 1 ,3-diol) claim 1 , morpholine claim 1 , epolamine claim 1 , piperidine claim 1 , picoline claim 1 , dicyclohexylamine claim 1 , N claim 1 ,N′-dibenzylethylenediamine claim 1 , 2-hydroxyethylamine claim 1 , tri-(2-hydroxyethyl)amine claim 1 , chloroprocaine claim 1 , choline claim 1 , deanol claim 1 , imidazole claim 1 , diethanolamine claim 1 , ethylenediamine claim 1 , meglumine (N-methylglucamine) claim 1 , procaine claim 1 , dibenzylpiperidine claim 1 , dehydroabietylamine claim 1 , glucamine claim 1 , collidine claim 1 , quinine claim 1 , quinolone claim 1 , erbumine claim 1 , lysine or arginine salt thereof.9. The compound according to claim 1 , wherein the compound is the sodium salt thereof.10. A pharmaceutical composition comprising one or more compounds according to and a pharmaceutically acceptable excipient.11. A pharmaceutical composition comprising one or more compounds according to claim 1 , another ...

Подробнее
Номер записи: 2
11-06-2020 дата публикации

COMPOSITIONS AND METHODS FOR ACTIVATING "STIMULATOR OF INTERFERON GENE" - DEPENDENT SIGNALLING

Номер: US20200179431A1
Автор: Dubensky, Gauthier Kelsey, Glickman Laura Hix, JR. Thomas W., Kanne David, Katibah George Edwin, Leong Justin, McWhirter Sarah M., SUNG Leonard
Принадлежит: Aduro Biotech, Inc.

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinucleotides present in the composition are 2′-fluoro substituted, bis-3′,5′ CDNs, and most preferably one or more 2′,2″-diF-Rp,Rp, bis-3′,5′CDNs. 1. (canceled)2. (canceled)4. The compound according to claim 3 , wherein R21 and R22 are both adenine.5. The compound according to claim 3 , wherein R21 is adenine and R22 is guanine.6. (canceled)7. (canceled)8. The compound according to claim 3 , wherein the compound is the sodium claim 3 , potassium claim 3 , calcium claim 3 , magnesium claim 3 , zinc claim 3 , aluminum claim 3 , ammonium claim 3 , diethylamine claim 3 , olamine claim 3 , benzathine claim 3 , benethamine claim 3 , tromethamine (2-amino-2-(hydroxymethyl)propane-1 claim 3 ,3-diol) claim 3 , morpholine claim 3 , epolamine claim 3 , piperidine claim 3 , picoline claim 3 , dicyclohexylamine claim 3 , N claim 3 ,N′-dibenzylethylenediamine claim 3 , 2-hydroxyethylamine claim 3 , tri-(2-hydroxyethyl)amine claim 3 , chloroprocaine claim 3 , choline claim 3 , deanol claim 3 , imidazole claim 3 , diethanolamine claim 3 , ethylenediamine claim 3 , meglumine (N-methylglucamine) claim 3 , procaine claim 3 , dibenzylpiperidine claim 3 , dehydroabietylamine claim 3 , glucamine claim 3 , collidine claim 3 , quinine claim 3 , quinolone claim 3 , erbumine claim 3 , lysine or arginine salt thereof.9. The compound according to claim 3 , wherein the compound is the sodium salt thereof.10. A pharmaceutical composition comprising one or more compounds according to and a pharmaceutically acceptable excipient.11. A pharmaceutical composition comprising ...

Подробнее
Номер записи: 3
27-12-2018 дата публикации

METHODS FOR IDENTIFYING INHIBITORS OF "STIMULATOR OF INTERFERON GENE"- DEPENDENT INTERFERON PRODUCTION

Номер: US20180369268A1
Автор: Dubensky, JR. Thomas W., Kanne David, Katibah George Edwin, Leong Justin, McWhirter Sarah M., SUNG Leonard
Принадлежит: Aduro Biotech, Inc.

The present invention relates to the use cyclic-di-nucleotide and related scaffold molecules that measurably inhibit STING signaling, and methods for their use in identifying more potent inhibitors of STING signaling. In particular, the methods provided can be used to identify potent inhibitors of STING signaling, which are useful in the treatment of autoimmune and inflammatory diseases. Also provided are compounds having STING inhibitory activity useful in the treatment of autoimmune and inflammatory diseases. 2. The scaffold molecule according to claim 1 , wherein the scaffold molecule measurably binds to one or more of wild type hSTING claim 1 , hSTING HAQ allele claim 1 , or hSTING REF allele.3. The scaffold molecule according to claim 2 , wherein binding to hSTING is measured by Tshift in a differential scanning fluorometry assay.4. The scaffold molecule according to claim 3 , wherein the Tshift is measured according to the assay of Example 11 claim 3 , and the Tshift is in the range of about 2 to about 15° C. for WT hSTING or hSTING REF allele and in the range of about 2 to about 25° C. for hSTING HAQ allele.5. The scaffold molecule according to claim 1 , wherein the measurable STING inhibitory activity is measured in a competition assay with a STING agonist.6. The scaffold molecule according to claim 5 , wherein the STING agonist is 2′3′-RR-(A)(A).7. The scaffold molecule according to claim 5 , wherein the scaffold molecule has an IC50 in the competition assay of less than 10 mM.8. The scaffold molecule according to claim 5 , wherein the scaffold molecule has an IC50 in the competition assay of less than 5 mM.9. The scaffold molecule according to claim 5 , wherein the scaffold molecule has an IC50 in the competition assay in the range of 100 μM to 5 μM.10. (canceled)11. The scaffold molecule according to wherein Xand Xare —SH.15. A method of identifying a STING inhibitor comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'a) providing a ...

Подробнее
Номер записи: 4
04-05-2017 дата публикации

Compositions and methods for activating "stimulator of interferon gene"-dependent signalling

Номер: WO2017075477A1
Автор: Chudi Obioma Ndubaku, David Kanne, George Edwin KATIBAH, Jeffrey Mckenna, Justin Leong, Kelsey GAUTHIER, Laura Hix Glickman, Leonard Sung, Sarah M. MCWHIRTER, Stephen M. CANHAM, Thomas W. Dubensky
Принадлежит: Aduro Biotech, Inc., NOVARTIS AG

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinuclotides present in the composition are 2'- or 3'-mono-fluoro substituted, or 2'3'-di-fluoro substituted mixed linkage 2',5' - 3',5' CDNs.

Подробнее
Номер записи: 5
17-04-2018 дата публикации

compositions and methods for activating interferon gene stimulator-dependent signaling

Номер: BR112017018908A2
Автор: Edwin Katibah George, Gauthier Kelsey, Hix Glickman Laura, Kanne David, Leong Justin, M. Mcwhirter Sarah, SUNG Leonard, W. Dubensky Thomas Jr.
Принадлежит: Aduro Biotech, Inc.

a presente invenção refere-se a estimuladores imunes de dinucleotídeos cíclicos (cdn) altamente ativos que ativam dcs através de um receptor citoplasmático recentemente descoberto conhecido como sting (estimulador de genes de interferon). em particular, os cdns da presente invenção são proporcionados na forma de uma composição compreendendo um ou mais dinucleotídeos de purina cíclicos induzindo a produção de interferon de tipo i dependente de sting humano, em que os dinuclotídeos de purina cíclicos presentes na composição são bis-3',5'cdns 2'-fluoro substituídos e, mais preferencialmente, um ou mais 2',2''-dif-rp, rp, bis-3',5'cdns. The present invention relates to highly active cyclic dinucleotide (cdn) immune stimulators that activate dcs via a newly discovered cytoplasmic receptor known as sting (interferon gene enhancer). in particular, the cdns of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides inducing the production of human sting-dependent interferon type I, wherein the cyclic purine dinuclotides present in the composition are bis-3. Substituted 2'-fluoro, 5'cdns and more preferably one or more 2 ', 2' '- dif-rp, rp, bis-3', 5'cdns.

Подробнее
Номер записи: 6
15-11-2017 дата публикации

COMPOSITIONS AND METHODS TO ACTIVATE THE DEPENDENT SIGNALING OF THE "INTERFERON GEN STIMULATOR"

Номер: DOP2017000205A
Автор: Edwin Katibah George, Gauthier Kelsey, Hix Glickman Laura, Kanne David, Leong Justin, M Mcwhirter Sarah, SUNG Leonard, W Dubensky Thomas Jr
Принадлежит: Aduro Biotech Inc

La presente invención proporciona estimuladores inmunitarios di-nucleótidos-cíclicos- (CDN) de gran actividad que activan DC a través de un receptor citoplasmático descubierto recientemente conocido como STING (Estimulador de genes de interferón). En particular, los CDN de la presente invención se proporcionan en forma de una composición que comprende uno o más dinucleótidos cíclicos de purina que inducen la producción de interferón de tipo I dependiente de STING humano, donde los dinuclotidas cíclicos de purina presentes en la composición son CDN bis-3',5' 2'-fluoro sustituidos, y más preferiblemente uno o más CDN bis-3’,5’ 2’,2’’-diF-Rp,Rp.

Подробнее
Номер записи: 7
26-04-2018 дата публикации

Compositions and methods for activating "stimulator of interferon gene"-dependent signalling

Номер: WO2017075477A8
Автор: Chudi Obioma Ndubaku, David Kanne, George Edwin KATIBAH, Jeffrey Mckenna, Justin Leong, Kelsey GAUTHIER, Laura Hix Glickman, Leonard Sung, Sarah M. MCWHIRTER, Stephen M. CANHAM, Thomas W. Dubensky, Jr.
Принадлежит: Aduro Biotech, Inc., NOVARTIS AG

The present invention provides highly active cyclic-di-nucleotide (CDN) immune stimulators that activate DCs via a recently discovered cytoplasmic receptor known as STING (Stimulator of Interferon Genes). In particular, the CDNs of the present invention are provided in the form of a composition comprising one or more cyclic purine dinucleotides induce human STING-dependent type I interferon production, wherein the cyclic purine dinuclotides present in the composition are 2'- or 3'-mono-fluoro substituted, or 2'3'-di-fluoro substituted mixed linkage 2',5' - 3',5' CDNs.

Подробнее
Номер записи: 8
07-09-2023 дата публикации

Modified viral compositions for viral transduction

Номер: US20230279426A1
Автор: Dallas Clifford JONES, Darrin Anthony Lindhout, Richard James GLYNNE, Sarah M. MCWHIRTER, Stephanie Ann PINKERTON, Tigran Arvid AIVAZIAN
Принадлежит: Lycia Therapeutics Inc

This disclosure provides compositions and methods for delivering a viral composition to cells, e.g., for cell surface receptor-mediated uptake, and enhanced viral transduction. Viral transduction can be achieved via a modified viral composition that includes a moiety that binds to a cell surface receptor ligand. Modified viral compositions and methods for reducing levels or titers of neutralizing antibodies in a subject in need of viral therapy, e.g., gene therapy, are provided. In some embodiments, the modified viral composition includes empty viral particles that bind and internalize neutralizing autoantibodies. Modified viral compositions including empty viral particles can be administered prior to viral therapy. Also provided are pharmaceutical compositions and kits including a modified viral composition.

Подробнее
Номер записи: 9
01-05-2024 дата публикации

Bifunctional compounds containing igf-2 polypeptides

Номер: EP4359430A2
Автор: Dallas Clifford JONES, Darrin Anthony Lindhout, Jason G. Lewis, Richard James GLYNNE, Sarah M. MCWHIRTER, Stephanie Ann PINKERTON, Tigran Arvid AIVAZIAN
Принадлежит: Lycia Therapeutics Inc

The present disclosure provides a class of bifunctional compounds that includes an IGF-2 polypeptide that specifically binds to a cell surface cation independent mannose-6-phosphate receptor (CI-M6PR), and a target binding moiety. The bifunctional compounds can trigger the CI-M6PR cell surface receptor to internalize into the cell a complex of the target and the bifunctional compound. The target can be an extracellular target protein such as a soluble protein or a membrane bound target protein. The target binding moiety can be an antibody or antibody fragment. Also provided are methods of using the bifunctional compounds for sequestration and/or lysosomal degradation of a target, e.g., an extracellular target protein associated with a disease or disorder of interest.

Подробнее
Номер записи: 10
27-01-2022 дата публикации

Modified viral compositions for viral transduction

Номер: WO2021263061A3
Автор: Dallas Clifford JONES, Darrin Anthony Lindhout, Richard James GLYNNE, Sarah M. MCWHIRTER, Stephanie Ann PINKERTON, Tigran Arvid AIVAZIAN
Принадлежит: Lycia Therapeutics, Inc.

This disclosure provides compositions and methods for delivering a viral composition to cells, e.g., for cell surface receptor-mediated uptake, and enhanced viral transduction. Viral transduction can be achieved via a modified viral composition that includes a moiety that binds to a cell surface receptor ligand. Modified viral compositions and methods for reducing levels or titers of neutralizing antibodies in a subject in need of viral therapy, e.g., gene therapy, are provided. In some embodiments, the modified viral composition includes empty viral particles that bind and internalize neutralizing autoantibodies. Modified viral compositions including empty viral particles can be administered prior to viral therapy. Also provided are pharmaceutical compositions and kits including a modified viral composition.

Подробнее
Номер записи: 11
12-01-2023 дата публикации

Modified viral compositions for viral transduction

Номер: WO2021263061A8
Автор: Dallas Clifford JONES, Darrin Anthony Lindhout, Richard James GLYNNE, Sarah M. MCWHIRTER, Stephanie Ann PINKERTON, Tigran Arvid AIVAZIAN
Принадлежит: Lycia Therapeutics, Inc.

This disclosure provides compositions and methods for delivering a viral composition to cells, e.g., for cell surface receptor-mediated uptake, and enhanced viral transduction. Viral transduction can be achieved via a modified viral composition that includes a moiety that binds to a cell surface receptor ligand. Modified viral compositions and methods for reducing levels or titers of neutralizing antibodies in a subject in need of viral therapy, e.g., gene therapy, are provided. In some embodiments, the modified viral composition includes empty viral particles that bind and internalize neutralizing autoantibodies. Modified viral compositions including empty viral particles can be administered prior to viral therapy. Also provided are pharmaceutical compositions and kits including a modified viral composition.

Подробнее
Номер записи: 12
12-01-2023 дата публикации

Bifunctional bridging compositions for viral transduction

Номер: WO2021263060A8
Автор: Dallas Clifford JONES, Darrin Anthony Lindhout, Richard G. YAU, Richard James GLYNNE, Sarah M. MCWHIRTER, Stephanie Ann PINKERTON, Tigran Arvid AIVAZIAN
Принадлежит: Lycia Therapeutics, Inc.

This disclosure provides compositions and methods for delivering a viral composition to cells, e.g., for cell surface receptor-mediated uptake, and enhanced viral transduction. Viral transduction can be achieved via a bifunctional bridging composition that includes a moiety that binds to a cell surface receptor ligand and a linked bridging moiety that binds to a viral composition. Also provided are modified viral compositions comprising a bridging composition specifically bound via its bridging moiety to the viral composition. Modified viral compositions and methods for reducing levels or titers of neutralizing antibodies in a subject in need of viral therapy, e.g., gene therapy, are provided. In some embodiments, the modified viral composition includes empty viral particles that bind and internalize neutralizing autoantibodies. Modified viral compositions including empty viral particles can be administered prior to viral therapy. Also provided are pharmaceutical compositions and kits including a bifunctional bridging composition and/or modified viral compositions.

Подробнее
Номер записи: 13
27-01-2022 дата публикации

Bifunctional bridging compositions for viral transduction

Номер: WO2021263060A3
Автор: Dallas Clifford JONES, Darrin Anthony Lindhout, Richard G. YAU, Richard James GLYNNE, Sarah M. MCWHIRTER, Stephanie Ann PINKERTON, Tigran Arvid AIVAZIAN
Принадлежит: Lycia Therapeutics, Inc.

This disclosure provides compositions and methods for delivering a viral composition to cells, e.g., for cell surface receptor-mediated uptake, and enhanced viral transduction. Viral transduction can be achieved via a bifunctional bridging composition that includes a moiety that binds to a cell surface receptor ligand and a linked bridging moiety that binds to a viral composition. Also provided are modified viral compositions comprising a bridging composition specifically bound via its bridging moiety to the viral composition. Modified viral compositions and methods for reducing levels or titers of neutralizing antibodies in a subject in need of viral therapy, e.g., gene therapy, are provided. In some embodiments, the modified viral composition includes empty viral particles that bind and internalize neutralizing autoantibodies. Modified viral compositions including empty viral particles can be administered prior to viral therapy. Also provided are pharmaceutical compositions and kits including a bifunctional bridging composition and/or modified viral compositions.

Подробнее
Номер записи: 14
22-08-2024 дата публикации

Bifunctional compounds containing igf-2 polypeptides

Номер: US20240279360A1
Автор: Dallas Clifford JONES, Darrin Anthony Lindhout, James Richard GLYNNE, Jason G. Lewis, Sarah M. MCWHIRTER, Stephanie Ann PINKERTON, Tigran Arvid AIVAZIAN
Принадлежит: Lycia Therapeutics Inc

The present disclosure provides a class of bifunctional compounds that includes an IGF-2 polypeptide that specifically binds to a cell surface cation independent mannose-6-phosphate receptor (CI-M6PR), and a target binding moiety. The bifunctional compounds can trigger the CI-M6PR cell surface receptor to internalize into the cell a complex of the target and the bifunctional compound. The target can be an extracellular target protein such as a soluble protein or a membrane bound target protein. The target binding moiety can be an antibody or antibody fragment. Also provided are methods of using the bifunctional compounds for sequestration and/or lysosomal degradation of a target, e.g., an extracellular target protein associated with a disease or disorder of interest.

Подробнее
Номер записи: 15